Fig. 2From: Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)Percent change from baseline in LDL-C levels over time for each treatment group during the double-blind treatment period (on-treatment estimand). LDL-C = low density lipoprotein cholesterol; LS = least squares; Q2W = every 2 weeks; Q4W = every 4 weeks; SE = standard errorBack to article page